Solid Biosciences (SLDB) Accounts Payables (2017 - 2026)

Solid Biosciences has disclosed Accounts Payables across 10 years of filings, most recently posting $5.6 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $5.6 million, down 13.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (down 13.6% YoY), and the FY2025 annual result was $3.2 million, down 23.91% from the prior year.
• Accounts Payables came in at $5.6 million for Q1 2026 at Solid Biosciences, up from $3.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $8.4 million in Q3 2025 to a low of $1.7 million in Q1 2024.
• The 5-year median for Accounts Payables is $4.2 million (2024), against an average of $4.2 million.
• Across the five-year window, Accounts Payables slumped 69.08% in 2024 and surged 272.2% in 2025, its largest moves.
• Solid Biosciences' Accounts Payables stood at $3.2 million in 2022, then plunged by 37.25% to $2.0 million in 2023, then jumped by 108.51% to $4.2 million in 2024, then slipped by 23.91% to $3.2 million in 2025, then surged by 72.55% to $5.6 million in 2026.
• The last three Accounts Payables figures came in at $5.6 million (Q1 2026), $3.2 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.